Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
105 hedge funds and large institutions have $1.55B invested in Rubius Therapeutics, Inc in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 33 reducing their positions, and 15 closing their positions.
169% more call options, than puts
Call options by funds: $3.1M | Put options by funds: $1.15M
9% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 33
3% less funds holding
Funds holding: 108 → 105 (-3)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
26% less capital invested
Capital invested by funds: $2.09B → $1.55B (-$541M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$26.1M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$5.2M |
| 3 |
Goldman Sachs
New York
|
+$4.5M |
| 4 |
Two Sigma Advisers
New York
|
+$2.42M |
| 5 |
Two Sigma Investments
New York
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$10.4M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.46M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$2.88M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.21M |
| 5 |
Citigroup
New York
|
-$1.98M |
RUBY Hedge Fund Activity: Q3 2021 in Review
105 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q3 2021, worth a combined $1.55B — down 26% from $2.09B a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of RUBY and 12 opened new positions — a net loss of 3 holders — while 33 trimmed existing stakes and 36 added.
The largest buyer was Capital World Investors, adding an estimated $26.1M. The largest seller was Artal Group, cutting an estimated $10.4M.
- 105 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q3 2021, down from 108 in Q2 2021.
- Funds reported $1.55B of Rubius Therapeutics, Inc stock for Q3 2021, down 26% quarter-over-quarter.
- 12 funds opened new Rubius Therapeutics, Inc positions in Q3 2021 and 15 closed out, a net change of -3 holders.
- The largest Rubius Therapeutics, Inc buyer in Q3 2021 was Capital World Investors, an estimated $26.1M added.
- The largest Rubius Therapeutics, Inc seller in Q3 2021 was Artal Group, an estimated $10.4M sold.
Based on aggregated 13F filings for Q3 2021.